Upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis and psoriatic arthritis, has shown potential benefits in PPP through several case reports [64,65,66,67]. This evidence concerns the gene JAK1 and atopic eczema.